News

Press Releases

Sep 28, 2023

Fractyl Health to Present Pioneering Data on Revita^® and Rejuva^® Programs at the European Association for the Study of Diabetes (EASD) 2023 Scientific Congress

LEXINGTON, Mass.--(BUSINESS WIRE)-- Fractyl Health, a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including type 2 diabetes (T2D) and obesity, announced tod...

Sep 14, 2023

Fractyl Health Welcomes Dr. Timothy Kieffer as Chief Scientific Officer

Seasoned Expert Joins to Drive Fractyl's Pioneering Mission Forward with its Revita® and Rejuva® Programs for Type 2 Diabetes and Obesity Dr. Kieffer’s Stellar Track Record Spans Pioneering Academic Research in Diab...

Aug 30, 2023

Fractyl Health Mourns the Passing of Esteemed Board Member Brian Dovey

LEXINGTON, Mass.--(BUSINESS WIRE)-- It is with profound sadness that Fractyl Health announces the passing of Brian Dovey, a cherished member of our Board of Directors and a partner at Domain Associates, following a shor...

Aug 1, 2023

Fractyl Health Announces Clinical Update on Revita Real World Registry in Germany and Launch of Revita+ Telehealth Program Combining Behavioral Recommendations with Revita Treatment for Type 2 Diabetes

Revita+ is a pioneering partnership between the West German Diabetes and Health Centre (WDGZ) and Fractyl Health, combining Revita with telehealth behavioral modification recommendations for patients with Type 2 Diabetes...

Aug 1, 2023

Fractyl Health gibt aktuelle Informationen zur Revita^® Real World Register Studie in Deutschland und zur Initiierung des Revita+™ Telehealth-Programms bekannt

Revita+ ist eine wegweisende Partnerschaft zwischen dem Westdeutschen Diabetes- und Gesundheitszentrum (WDGZ) und Fractyl Health, die Revita mit Empfehlungen zu Änderungen des Lebensstils für Patienten mit Typ-2-Diabet...

Jun 26, 2023

Fractyl Health Reports Durable Improvement in Glucose Control, Weight Loss, and Insulin Reduction in T2D Patients Using Revita^® in Open Label Phase of Revitalize 1 Pivotal Study at the American Diabetes Association 83rd Scientific Sessions

Revita®, in conjunction with empagliflozin, provided a median HbA1c reduction of 1.6% and weight loss of 9.3% after 48 weeks while reducing insulin use by 44% in this inadequately controlled, insulin-dependent cohort R...

Jun 24, 2023

Fractyl Health Demonstrates Significant Improvement in Glucose Control and Obesity in Preclinical Studies of its Rejuva GLP-1 Based Pancreatic Gene Therapy (GLP1 PGTx) Compared to Chronic Semaglutide at ADA’s 83rd Scientific Sessions

Revolutionary one-time pancreatic gene therapy resulted in up to 54% lower blood glucose and 20% lower total bodyweight than chronic semaglutide 10 nmol/kg/day in the db/db rodent model Proprietary Fractyl delivery tech...

Jun 13, 2023

Fractyl Health to Present Landmark Updates on Revita^® and Rejuva^® Programs at the 83rd American Diabetes Association

LEXINGTON, Mass.--(BUSINESS WIRE)-- Fractyl Health, an organ-editing metabolic therapeutics company pioneering new approaches to prevent and reverse type 2 diabetes (T2D), announced today its participation in the upcomin...

May 18, 2023

Fractyl Health Unveils Groundbreaking Pre-Clinical Proof of Concept Results for its Rejuva^® Pancreatic Gene Therapy Platform for Metabolic Diseases at the American Society of Gene & Cell Therapy Congress

Rejuva device & procedure reliably and successfully targets pancreas with Adeno Associated Virus (AAV), potentially enabling gene therapy to address pancreatic diseases for the first time Rejuva platform and genet...

May 9, 2023

Fractyl Health to Present Preclinical Proof-of-Concept Data for Rejuva^® Pancreatic Gene Therapy Platform Program at the American Society of Gene & Cell Therapy Congress

LEXINGTON, Mass.--(BUSINESS WIRE)-- Fractyl Health, an organ-editing metabolic therapeutics company focused on pioneering new approaches to the treatment of type 2 diabetes (T2D), announced today that it will be presenti...

The press releases contained in this section of the website are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. Fractyl Health disavows any obligation to update the information contained in such press releases after the date of their issuance.

Media Contact: Beth Brett, Corporate Communications
Bbrett@fractyl.com , +1 (720) 656-6544

Electronic Press Kit